Leonabio Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Leonabio Inc 's ROA in the second quarter of 2026?
Leonabio Inc recorded a cumulative net loss of $-141 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -111.03%.

However, within the Healthcare sector 867 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4515, from total ROA ranking in the first quarter of 2026 at 5206.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	214.1 %	64.53 %	404.2 %	-65.18 %	-81.85 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-141	-129	-106	-38	-60
Return On Assets (TTM)	-111.03 %	-119.41 %	-104.19 %	-89.89 %	-106.84 %
LONA's Total Ranking	# 4515	# 5206	# 4353	# 4482	# 4546
Total Assets (TTM) in million	112	72	296	30	36
Seq. Total Assets Change	55.95 %	-75.84 %	886.78 %	-15.51 %	-18.31 %
Seq. Net Income Change	-	-	-	-	-

LONA's 5 Years Annual ROA >> Back to LONA Management Effectiveness >> Compare LONA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 132
Sector	# 868
Overall	# 4467

Return On Assets Statistics
High	Average	Low
-7.15 %	-77.68 %	-225.74 %
(Jun 30 2021)		(Mar 31 2026)

Financial Statements
Leonabio Inc 's Assets	$ 112 million	LONA's Balance sheet
Leonabio Inc 's Income	$ -19 million	Quarterly LONA's Income Statement
LONA's Income by Division		See LONA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	404.2 %	-63.29 %	-38.04 %	-22.17 %	18.76 %
Total Assets in million	296	59	160	258	332
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-106	-97	-118	-96	-55
Annual Return On Assets	-35.64 %	-164.92 %	-73.49 %	-37.01 %	-16.52 %

LONA's 5 Years Annual ROA >> Back to LONA Management Effectiveness >> Compare LONA ROA to its Competitors

More Return On Assets Ratios
LONA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LONA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LONA's Competitors
Subscribers only: Roa for Leonabio Inc 's Suppliers
Subscribers only: Return On Assets for LONA's Customers

You may also want to know
LONA's Roi	LONA's Inventory Turnover Ratio	LONA's Growth Rates	LONA's Dividend Comparisons
	LONA's Profitability Ratios	LONA's Asset Turnover Ratio	LONA's Dividend Growth
LONA's Roe	LONA's Valuation Ratios	LONA's Financial Strength Ratios	LONA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-31T02:55:08+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.